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Leptin G-2548A Promoter Polymorphism is Associated with 
Increased Plasma Leptin and BMI in Brazilian Women
ABSTRACT
Variants in leptin gene (LEP) have been implicated in the pathogenesis of 
obesity. The relationship between LEP G-2548A polymorphism and obesity-
related traits was evaluated in a sample of Brazilian women (n = 228) who 
were randomly selected from two clinical centers in Sao Paulo city. Blood 
samples were collected for DNA extraction, plasma leptin and serum lipids 
measurements. LEP G-2548A genotypes were identified by a PCR- RFLP strat-
egy using the endonuclease Alw44I. LEP G-2548A was associated with obe-
sity after adjustment for covariates (age, hypertension, coronary artery 
disease, smoking and physical activity). Women carrying G allele had a four 
times higher risk of obesity than the A allele carriers (OR: 4.11, CI95%:
1.06-15.90, p = 0.041). G allele was also related to increased plasma leptin (p 
= 0.024) and body mass index (p = 0.027). Hypertension, hyperglycemia, dys-
lipidemia and coronary artery disease were associated with obesity. However 
LEP G-2548A polymorphism was not related to these variables. All together 
these data suggest that LEP G-2548A polymorphism has an important role in 
regulating plasma leptin levels and body mass index in women. (Arq Bras 
Endocrinol Metab 2008; 52/4:611-616)
Keywords: Leptin; Gene polymorphism; Body mass index; Obesity; PCR-RFLP.
RESUMO
Polimorfismo do Promotor do Gene da Leptina está Associado ao Aumento 
de Leptina Plasmática e IMC em Mulheres Brasileiras.
Variantes no gene da leptina (LEP) foram implicados na patogênese da obesi-
dade. A relação entre o polimorfismo LEP G-2548A e as características rela-
cionadas com a obesidade foram avaliadas em mulheres brasileiras (n = 228), 
que foram selecionadas randomicamente de dois centros de pesquisa clínica 
na cidade de São Paulo. As amostras de sangue foram coletadas para extra-
ção de DNA e determinações de leptina plasmática e lipídeos séricos. Os
genótipos do LEP G-2548A foram identificados pela estratégia de PCR-RFLP, 
empregando a endonuclease Alw44I. O polimorfismo LEP G-2548A foi asso-
ciado com obesidade, após ajuste para as covariáveis: idade, hipertensão, 
doença arterial coronariana, tabagismo e atividade física. Mulheres com alelo 
G tiveram quatro vezes maior risco de obesidade que as portadoras do alelo 
A (OR: 4,11, CI95%: 1,06-15,90; p = 0,041). O alelo G também foi relacionado 
com leptina plasmática (p = 0,024) e o índice de massa corporal (p = 0,027) 
aumentado. A hipertensão, a hiperglicemia, a dislipidemia e a doença arterial 
coronariana foram associadas com obesidade. Entretanto, o polimorfismo 
LEP G-2548A não foi relacionado com essas variáveis. Os resultados deste 
estudo são sugestivos de que o polimorfismo LEP G-2548A tem papel impor-
tante na regulação da leptina plasmática e no índice de massa corporal em 
mulheres. (Arq Bras Endocrinol Metab 2008; 52/4:611-616)
Descritores: Leptina; Polimorfismo genético; Índice de massa corporal; Obe-
sidade; PCR-RFLP.
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INTRODUCTION
The prevalence of obesity is increasing in most of industrialized countries and has become an impor-
tant issue of public health. Excessive bodyweight is 
considered the sixth most important risk factor contri-
buting to the overall burden of disease worldwide (1). 
Obesity has a complex pathogenesis that results from 
interactions between genetic and environmental factors 
that lead to the malfunction of several signaling pepti-
des, which are involved in body energy balance and nu-
tritional status (2,3).
Leptin is a metabolic and neuroendocrine hormone 
produced and released mainly by adipocytes (4,5). It has 
several systemic effects such as body mass control, repro-
duction, angiogenesis, immunity, wound healing, bone 
remodelling and cardiovascular function (4,6). Plasma 
leptin concentration is proportional to body adiposity 
and is markedly increased in obese individuals (4).
Several studies have suggested that variants in the 
leptin gene (LEP) may be important to the pathophy-
siology of human obesity (7,8). A common single nu-
cleotide polymorphism within the 5’ promoter region 
(G-2548A) of LEP has been associated with variations 
in plasma leptin and body mass index (BMI) in obese 
individuals (9-11). It has been shown that the G-2548A 
LEP polymorphism influences leptin expression, possi-
bly at the transcriptional level, and therefore also adi-
pose secretion levels of the hormone (12).
In this study, the influence of the LEP G-2548A 
polymorphism on plasma leptin and obesity-related 
traits was evaluated in a sample of Brazilian women.
SUBJECTS AND METHODS
Study group
Blood samples were obtained from 228 unrelated Bra-
zilian women, who were selected from Instituto do Co-
ração/Faculdade de Medicina/Universidade de Sao 
Paulo (FMUSP) and Instituto Dante Pazzanese de 
Cardiologia (IDPC), Sao Paulo, Brazil.  Although the-
se individuals were declared non-Africans by physical 
evaluation, a lack of relationship between color and ge-
nomic ancestry have been found in Brazilian samples 
(13). The study was previously approved by the FMUSP 
and IDPC Ethical Committees and written consent 
was obtained from each participant.
Anthropometrics measurements, such as BMI, waist 
circumference (WC) and waist-to-hip ratio (WHR) were 
taken from each participant (14). Systolic/diastolic 
blood pressure was measured in supine position after res-
ting for 30 min. Based on World Health Organization 
recommendations, people with BMI higher than 30 kg/
m² were classified as obese (15) and those with systolic/
diastolic blood pressure over 140/90 mmHg or under 
lowering-pressure therapy were considered hypertensive 
(16). The presence of coronary artery disease (CAD) 
was investigated by coronary angiography.
Biochemical analyses
A 12-hour fasting blood sample was collected from 
each participant for serum lipids,  plasma glucose and 
leptin determinations. Glucose, triglycerides,  total 
cholesterol and high-density lipoprotein (HDL) cho-
lesterol were measured by enzymatic-colorimetric as-
says using a Roche-Hitachi 912 automated analyzer 
(Hitachi, Nakakojo, Japan). Low-density lipoprotein 
(LDL) and very low-density lipoprotein (VLDL) cho-
lesterol were calculated by Friedewald formulae (17). 
Plasma leptin was determined by ELISA method (Ale-
xis Biochemical/Vendor BioAgency, Sao Paulo, Brazil). 
The Atherogenic Index of Plasma (AIP) calculated as 
log (triglyceride/HDL cholesterol) and the apolipo-
protein B/apolipoprotein AI (apoB/ApoAI) ratio were 
also estimated (18,19).
DNA extraction and LEP G-2548A
genotyping
Genomic DNA was extracted from 1 mL EDTA-anti-
coagulated whole blood by a salting-out method (20). 
G-2548A LEP polymorphism was detected by a PCR-
RFLP strategy using the endonuclease Alw44I (Fer-
mentas, Vilnius, Lithuania). The primers used in PCR 
assays were designed based on the LEP promoter se-
quence previously described (21). The forward primer 
(5’ -CTTTTGTTTTGTTTTGCGACAGGGG-
TGC-3’) creates a recognition site for Alw44I endonu-
clease that allows the detection of the A allele. The 
reverse primer (5’-GCTCCCTTTGCCCGACCC-
CG-3’) generates a PCR product with a constitutive 
site for Alw44I that is useful as an internal control for 
restrictive reaction.
Genomic DNA (50 ng) was amplified in 50 µL assays 
containing primers 200 nmol/L (Life Technologies, Sao 
Paulo, Brazil), dNTPs 200 µmol/L (Amersham Bioscien-
ce, USA), DNA polymerase 1 U and PCR buffer [50 mM 
KCl, 2 mmol/L MgCl2, 20 mmol/L (NH4)2SO4, 75 
mmol/L Tris-HCl, pH 9,0] (Biotools, Madrid, Spain). 
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PCR assays were carried out in a PTC-200™ Thermal 
Cycler (M&J Research, Inc., Watertown, USA). After ini-
tial denaturation at 96ºC for 3 min, amplification was 
performed using 30 cycles at 96ºC for 30 s and 70ºC for 
90 s, followed by final extension at 72ºC for 10 min. PCR 
products were incubated with 4 U of Alw44I (Fermentas, 
Vilnius, Lithuania) at 37oC for 2 hs. PCR and restriction 
products were separated on 2% agarose gel electrophore-
sis at 100 V for 45 min and analyzed under UV light after 
ethidium bromide staining. 
The accuracy of the genotyping was evaluated by 
performing duplicate analysis of 20% samples randomly 
selected. Moreover, a heterozygous LEP G-2548A 
polymorphism sample (control sample) was included 
in each run.
Statistical analysis
Categorical variables were compared by chi-square test. 
The agreement of genotypes frequencies with Hardy-
Weinberg equilibrium expectations was tested using 
the chi-square test. Continuous variables were presen-
ted as means ± SD and compared by t-test. Variables 
without normal distribution (BMI, WC, leptin, glucose 
and lipid profile) were log transformed for analysis. Re-
lationships between the genotypes and categorical va-
riables (obesity, diabetes, hypertension, smoking, 
physical activity and CAD) were evaluated by either the 
chi-square test or Exact Fisher test. 
Logistic Regression Analysis was used to establish 
correlations between obesity and independent variables. 
Multivariate Logistic Regression Analysis with Stepwise 
criteria for variable selection was used to establish corre-
lation with obesity. The relation between LEP G-2548A 
alleles and the dependent variables (BMI, WC and 
WHR) was evaluated by Univariate Linear Regression 
Analysis. The results of these analyses were adjusted for 
the covariates: age, hypertension, diabetes, smoking, 
physical activity and CAD. The main predictors in the 
linear model were the LEP alleles. Statistical tests were
performed by SAS System for Windows software version 
8.02 (SAS Institute Inc, 1999-2001, Cary, NC, USA). 
Significance was assumed for P < 0.05.
RESULTS
Anthropometric and clinical data of women are shown 
in Table 1. Obese individuals exhibited mean age, BMI, 
waist circumference, waist-hip ratio and plasma leptin 
values higher than the non-obese group (p < 0.05). 
Hypertension, diabetes, CAD, physical activity and me-
nopause were also more frequent in the obese group (p
< 0.05). As expected, G-2548A LEP genotype distribu-
tions did not differ from those expected under Hardy-
Weinberg equilibrium (data not shown). There was no 
difference in genotype and allele frequencies between 
obese and non-obese groups (p = 0.304).
Table 1. Anthropometric, clinical, and LEP G-2548A polymorphism data in women.
Obese (100) Non-obese (128) P value
Age (yrs) 52 r 11 47 r 13 < 0.001
BMI (kg/m2)* 34.6 r 4.1 23.7 r 2.8 < 0.001
Waist circumference* 106.4 ± 9.2 84.8 ± 10.9 < 0.001
Waist-hip ratio 0.90 r 0.05 0l.85 r 0.07 < 0.001
Leptin* 41.9 r 19.6 15.7 r 13.1 < 0.001
CAD 14% 1% 0.004
Diabetes 23% 0% < 0.001
Hypertension 72% 10% < 0.001
Physical activity 79% 63% 0.032
Menopause 67% (67) 47% (60) 0.01
Smoking 35% 27% 0.340
LEP G-2548A
Genotype GG 40.0% 30.5% 0.304
Genotype GA 48.0% 53.9%
Genotype AA 12.0% 15.6%
G allele 64% 58% 0.133
Number of individuals in parenthesis. Individuals with BMI t 30 kg/m² were classified as obese (15) and those with systolic/diastolic blood pressure over to 140/90 mmHg 
or under anti-hypertensive therapy were considered hypertensive (16); Continuous variables are presented as mean ± SD and were compared by t-test. Categorical 
variables were compared by qui-square or Exact Fisher test;(*) Values were log transformed.
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Univariate logistic regression analysis showed that 
women with hypertension and CAD had high risk (ele-
ven times) of obesity (Table 2). Increased age, plasma 
Analyses of LEP G-2458A polymorphism showed 
that women carrying –2548G allele (GG genotype) 
had four times higher risk of obesity (OR: 4.11, 95% 
CI: 1.06-15.90) than the –2548A allele carriers (p =
0.041) when the variable was adjusted to the covariates 
age, hypertension, CAD, smoking and physical activity 
Table 2. Univariate logistic regression analysis of the variables associated with obesity.
Variables P value Odds Ratio 95% Confidence Interval
CAD 0.021 11.61 1.45-93.28
Hypertension < 0.001 24.51 9.63-62.40
Physical activity 0.034 2.23 1.06-4.68
Age < 0.001 1.04 1.02-1.07
Leptin < 0.001 1.10 1.07-1.13
Glucose < 0.001 1.1 1.06-1.14
Total cholesterol 0.066 1.01 0.99-1.01
LDL cholesterol 0.056 1.01 0.99-1.01
HDL cholesterol < 0.001 0.96 0.94-0.98
VLDL cholesterol < 0.001 1.08 1.05-1.11
Triglycerides < 0.001 1.01 1.01-1.02
ApoAI 0.057 0.99 0.98-1.01
ApoB < 0.001 1.03 1.1-1.04
ApoB/ApoAI ratio < 0.001 36.69 6.28-214.28
AIP < 0.001 30.28 9.19-99.74
LEP G allele adjusted* 0.041 4.11 1.06-15.90
(*) Adjusted to the covariates: age, hypertension, CAD, smoking and physical activity.
ApoAI, apolipoprotein I; ApoB, apolipoprotein B; AIP, atherogenic index of the plasma; CAD, coronary artery disease; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; VLDL, very low-density lipoprotein.
leptin and glucose, and serum triglycerides, VLDL 
cholesterol, apoB, apoB/ApoAI ratio and AIP were 
also associated with obesity in our sample (p < 0.001). 
(Table 2). Univariate linear regression analyses showed 
that –2548G allele is associated with plasma leptin (R2:
2.70, p = 0.024) and BMI (R2: 2.07, p=0.027) but not 
with waist circumference or waist-hip ratio (Table 3). G 
allele contributes to the increase in 0.18 log units for 
leptin and 0.04 log units for BMI.
Table 3. Univariate linear regression analysis of the variables associated with LEP G-2548A polymorphism.
Dependent variables LEP G-2548A P value R2 (%) Estimate (SE)
Body mass index A allele 0.394 0.31 –0.01 (0.01)
G allele 0.027 2.07 0.04 (0.02)
Waist circumference A allele 0.523 0.18 –0.01(0.01)
G allele 0.167 0.85 0.02 (0.01))
Waist-hip ratio A allele 0.900 0.01 –0.01 (0.01)
G allele 0.790 0.04 0.01 (0.01)
Plasma Leptin A allele 0.876 0.01 0.01 (0.06)
G allele 0.024 2.74 0.18 (0.08)
Variables were adjusted to the covariates: age, hypertension, diabetes, CAD, smoking and physical activity. Estimate indicates variation of log values.
Results from multivariate logistic regression analysis with Stepwise criterion for variable selection indicate that the risk of obesity was nine times higher in hypertensive 
women (O.R.: 9.06, 95% CI: 2.67-30.80, p < 0.001) (data not shown). Other predictors for obesity found in our sample are increased plasma leptin (O.R.: 1.08, 95% CI: 
1.05-1.12, p < 0.001) and serum apoB (O.R.: 1.03, 95% CI: 1.01-1.05, p < 0.001), and reduced HDL cholesterol (O.R.: 0.93, 95% CI: 0.89-0.97).
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DISCUSSION
The frequency of the LEP -2548G allele (64%) obser-
ved in Brazilian obese women was similar to that found 
in European overweight women and obese girls 
(10,11), as well as in North Americans (22). Our re-
sults clearly demonstrate that women carrying –2548G 
allele have at least four times more risk of obesity than 
non-carriers suggesting that LEP G-2548A polymor-
phism is a strong obesity predictor.
An association of LEP G-2548A polymorphism 
and increased BMI was also found in overweight Euro-
peans (10) and in a sample of Taiwanese Aborigines 
with extreme obesity (23). In addition, common va-
riants located in the 5´region of the LEP, including G-
2548A, were associated with increased BMI in men 
(24). On the other hand, other studies have failed to 
demonstrate association among these polymorphisms 
and obesity or increased BMI (25-28). 
The relationship between LEP –2548G allele and 
increased plasma leptin concentrations found in this 
sample was also described in obese and diabetic indivi-
duals from European and Asian populations (11,29). 
This allele was associated with plasma free leptin levels 
through an interaction with adiposity and gender in he-
althy individuals from Greece (30). On the other hand, 
-2458AA genotype was associated with increased plas-
ma leptin in obese individuals and in men from France 
cohorts (9,10). These different results may be due to 
interactions of G-2548A polymorphism with other va-
riants in leptin and/or leptin receptor genes, as well as 
other variables such as gender, sample size and popula-
tion, or the model used in genetics analyses. 
The G-2548A polymorphism is located at the 5’end 
of the promoter region of LEP and it has been suggested 
that this remote region may contain inhibitory elements 
for transcription in adipocytes (21). Even though this 
polymorphism is close to a SP-1 transcription factor bin-
ding site, as well as two repetitive sequences MER11 and 
Alu that maybe regulate LEP transcription, the effect of 
the G to A substitution at –2548 nucleotide in leptin 
expression remains to be elucidated.
In this study, obesity was associated with hyperten-
sion and other CAD-related risk factors such as advan-
ced age, diabetes, dyslipidemia, smoking, and increased 
apoB/apoAI ratio and AIP. However, our data do not 
support association of the LEP G-2548A with CAD, as 
it has been recently demonstrated for the LEP-tet mi-
crosatellite polymorphism in Italians and Brazilians 
(31,32).
Positive correlations between leptin and glucose, 
lipids, apoB/apoAI ratio and AIP values suggest its 
possible role as risk factor for CAD. A relationship 
among leptin, adiponectin, and abdominal obesity with 
cardiovascular risk assessed by apoB/ApoI ratio was re-
cently demonstrated  in Asian Indian and Caucasian 
populations (33). Leptin exerts many potentially athe-
rogenic effects such as induction of endothelial dys-
function, stimulation of inflammatory reaction, 
oxidative stress, decrease in paraoxonase activity, plate-
let aggregation, migration, hypertrophy and prolifera-
tion of vascular smooth muscle cells (34). These effects 
may contribute to the pathogenesis of hypertension, 
atherosclerosis, and left ventricular hypertrophy fre-
quently associated with obesity (35,36).
In conclusion, LEP G-2548A polymorphism is an 
important predictor for increased plasma leptin and 
BMI in Brazilian women and it maybe a useful marker 
for obesity-related risk in this population.
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